河北医学2017，Vol.23Issue(10)：1598-1602,5.DOI:10.3969/j.issn.1006-6233.2017.10.005
曲妥珠单抗联合伊沙匹隆治疗晚期转移性乳腺癌的疗效观察
Efficacy of Trastuzumab and Ixabepilone in the Treatment of Advanced Metastatic Breast Cancer
摘要
Abstract
Objective:To investigate the efficacy of trastuzumab in combination with ixabepilone treat-ment of advanced metastatic breast cancer. Methods:92 patients with HER-2 positive advanced breast cancer patients in our hospital were selected,the control group ( 45 cases) with trastuzumab treatment, study group ( 47 cases) with trastuzumab combined with ixabepilone treatment. The clinical efficacy was compared between the two groups. Results: After treatment, the total effective rate of treatment group was significantly higher than the control group,the difference was statistically significant ( P < 0.05);For the disease control rate of two groups,disease control rate of study group was significantly higher than the control group, the difference was statistically significant (P < 0.05); For the patients of two groups before treatment, the level of serum tumor markers in comparison,no statistically significant difference ( P > 0.05);after treatment,patients with serum levels of tumor markers of two groups were lower than before treatment;compared with the group before treatment,the difference was statistically significant ( P < 0.05);while the serum tumor research after treat-ment the levels of markers was significantly lower than the control group,the difference was statistically signifi-cant (P < 0.05); There was no statistically significant difference in adverse reaction rates between the two groups (P > 0.05). Conclusion: Trastuzumab combined with ixabepilone for patients with metastatic breast cancer can reduce the CEA,CA125 and CA15-3 levels,and drug safety,has clinical value.关键词
曲妥珠单抗/伊沙匹隆/HER2阳性乳腺癌Key words
Trastuzumab/Ixabepilone/HER2-positive breast cancer引用本文复制引用
黄任平..曲妥珠单抗联合伊沙匹隆治疗晚期转移性乳腺癌的疗效观察[J].河北医学,2017,23(10):1598-1602,5.基金项目
黑龙江省卫生和计划生育委员会科研课题,(编号:2016-004) （编号:2016-004）
